In patients with localized prostate cancer, is radical prostatectomy alone a definitive one-time treatment without postoperative drugs or radiation, and what are its side effects, long‑term consequences, effectiveness, and risk of recurrence?

Is Prostatectomy Alone a One-Time Treatment for Localized Prostate Cancer?

Radical prostatectomy alone is NOT reliably a one-time definitive treatment—approximately one-third of patients will experience cancer recurrence within a decade, and many will require additional therapy such as salvage radiotherapy or hormonal treatment based on adverse pathologic findings. 1

Understanding Recurrence Risk After Surgery Alone

The reality is that surgery-only outcomes depend heavily on what pathologists find in the removed prostate:

• For favorable disease (cancer confined to prostate): ~92% remain progression-free at 10 years 2
• For adverse pathology (extracapsular extension only): ~71% progression-free at 10 years 2
• For seminal vesicle invasion: ~37% progression-free at 10 years 2
• Overall across all risk groups: ~75% progression-free at 10 years 2

Biochemical recurrence (rising PSA ≥0.2 ng/mL) occurs in approximately 33% of patients within 10 years 1, and this PSA recurrence is associated with higher risk of metastatic disease and death from prostate cancer 1.

When Additional Treatment Becomes Necessary

The guidelines are clear that patients with adverse pathologic findings should be offered adjuvant radiotherapy because it demonstrably reduces:

• Biochemical (PSA) recurrence
• Local recurrence
• Clinical progression of cancer 1

Adverse pathologic findings requiring consideration of additional therapy include:

• Positive surgical margins
• Seminal vesicle invasion
• Extraprostatic extension
• Gleason score 8-10
• Detectable postoperative PSA 1

The highest-risk patients (seminal vesicle invasion, Gleason 8-10, extensive positive margins, detectable postoperative PSA) face the greatest recurrence risk and derive the most absolute benefit from adjuvant treatment 1.

Side Effects and Long-Term Consequences

Urinary Complications

• Urinary incontinence: 13-30% report some degree of incontinence long-term 3, 4, 5
  • Severe incontinence is uncommon (very low rates with modern technique)
  • Light incontinence persists in up to 30% even with long-term follow-up 4
• Urinary bother: 18% at 1 year 5
• Anastomotic stricture: 2-9% with modern techniques (historically 10-20%) 4

Sexual Function

• Erectile dysfunction: 73% at 1 year post-surgery 5
  • Risk depends on age, pre-operative function, nerve-sparing technique, and comorbidities (smoking, diabetes) 4
  • In selected subgroups with nerve-sparing surgery, ED risk can be lower
  • Recovery relates directly to preservation of cavernous nerves 3

Bowel Function

• Urgency to defecate: 14% at 1 year (significantly lower than radiotherapy at 34%) 5

Other Complications

• Inguinal hernia: 15-20% within 3 years after open retropubic approach 4
• Perioperative mortality: Very low, approximately 0.1% 4

Long-Term Quality of Life

• High quality of life reported by 85% at 1 year 5
• At 15 years follow-up, functional differences between surgery and radiation largely equalize 3
• Compared to baseline, patients experience significantly worse urinary incontinence and sexual function that persists long-term 6

Effectiveness and Cancer Recurrence

Cancer Control

Surgery provides excellent cancer control for organ-confined disease but effectiveness diminishes with adverse features:

• 10-year cancer-specific survival: 97.6% overall 2
• 10-year metastasis-free survival: 84.2% 2
• Randomized trial data (SPCG-4) showed surgery superior to watchful waiting in preventing:
  • Local progression (64% risk reduction)
  • Distant metastasis (35% risk reduction)
  • Death from prostate cancer (35% risk reduction) 3

The Recurrence Reality

Yes, cancer frequently recurs after prostatectomy alone:

• Biochemical recurrence (detectable/rising PSA) is the most common form of recurrence 1, 7
• Risk factors for recurrence include:
  • Positive surgical margins (present in 12.8% of cases) 2
  • Higher Gleason score
  • Extraprostatic extension
  • Seminal vesicle invasion
  • Lymph node involvement
  • Detectable postoperative PSA 1, 7

When recurrence occurs, salvage radiotherapy should be offered if there's no evidence of distant metastatic disease 7. Importantly, salvage radiotherapy is most effective when administered at lower PSA levels 1, 7, which is why regular PSA monitoring after surgery is critical.

Common Pitfall to Avoid

The major pitfall is assuming surgery alone will be curative for all localized disease. Patients must be counseled preoperatively that approximately one-third will need additional treatment, and the actual risk depends on final pathology that won't be known until after surgery 1. The decision between immediate adjuvant radiotherapy versus waiting for PSA recurrence (salvage approach) involves trade-offs: adjuvant therapy treats some who would never recur (unnecessary toxicity), while salvage therapy risks allowing progression to metastatic disease in high-risk patients 7.

The 12-year hazard risk of urinary or sexual complications is 7.23 times greater after prostatectomy compared to untreated patients 8, emphasizing that treatment decisions must carefully weigh cancer control benefits against quality-of-life impacts.